ACA
BIO icon

AYAL Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

AYAL Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Buy
+16,333
New +$4.63M 1.3% 29
2026
Q1 		– Sell
-20,000
Closed -$6.06M – 58
2025
Q4 		$6.06M Buy
20,000
+2,500
+14% +$780K 2.11% 12
2025
Q3 		$4.91M Buy
+17,500
New +$4.76M 1.93% 20
2025
Q1 		– Sell
-13,600
Closed -$4.47M – 45
2024
Q4 		$4.47M Buy
+13,600
New +$4.62M 1.15% 29

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AYAL Capital Advisors's BIO Position: Q2 2026 in Review

AYAL Capital Advisors opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 16,333 shares worth $4.8M. The stake represents 1.3% of the portfolio and ranks #29 among its holdings. This is a return to the name: AYAL Capital Advisors previously reported a position in BIO as recently as Q4 2025.

AYAL Capital Advisors first reported a position in BIO in Q4 2024 and has held it in 4 quarters since. The position peaked at $6.06M in Q4 2025. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • AYAL Capital Advisors held 16,333 shares of Bio-Rad Laboratories Class A worth $4.8M as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new AYAL Capital Advisors position in Q2 2026.
  • Bio-Rad Laboratories Class A made up 1.3% of AYAL Capital Advisors's portfolio in Q2 2026, its #29 holding.
  • AYAL Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and has held it in 4 quarters since.
  • AYAL Capital Advisors's Bio-Rad Laboratories Class A position peaked at $6.06M in Q4 2025.
  • 399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on AYAL Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.